Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.64 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | STAT6 | P42226 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL173508 | 1.00 | HSD17B10 (0.64) | HSD17B10SLC6A9ALDH1A1SMN1; SMN2STAT6 | |
| SCHEMBL321989 | 1.00 | HSD17B10 (0.64) | HSD17B10SLC6A9ALDH1A1SMN1; SMN2STAT6 | |
| SCHEMBL3660521 | 1.00 | — | — | |
| Tetraxetan SCHEMBL2017956 | 1.00 | HSD17B10 (0.64) | HSD17B10SLC6A9ALDH1A1SMN1; SMN2STAT6 | |
| SCHEMBL6848102 | 1.00 | HSD17B10 (0.64) | HSD17B10SLC6A9ALDH1A1SMN1; SMN2STAT6 | |
| Tetraxetan SCHEMBL18018 | 1.00 | HSD17B10 (0.64) | HSD17B10SLC6A9ALDH1A1SMN1; SMN2STAT6 | |
| SCHEMBL3503521 | 1.00 | HSD17B10 (0.64) | HSD17B10SLC6A9ALDH1A1SMN1; SMN2STAT6 | |
| Tetraxetan SCHEMBL2635294 | 1.00 | HSD17B10 (0.64) | HSD17B10SLC6A9ALDH1A1SMN1; SMN2STAT6 | |
| Tetraxetan SCHEMBL23647851 | 0.97 | HSD17B10 (0.61) | HSD17B10SLC6A9ALDH1A1SMN1; SMN2STAT6 | |
| Tetraxetan SCHEMBL15766009 | 0.97 | HSD17B10 (0.61) | HSD17B10SLC6A9ALDH1A1SMN1; SMN2STAT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4610269-A1 | UROKINASE PLASMINOGEN ACTIVATOR SURFACE RECEPTOR (UPAR) LIGANDS FOR DIAGNOSTIC OR THERAPEUTIC USE | 3B Pharmaceuticals GmbH (DE) | 2025-09-03 | — | — | EP | disclosed |
| CN-119684401-A | Compounds comprising a linker, a chelator, a ligand binding entity, methods of preparation and uses thereof | 赛诺哈勃药业（成都）有限公司 | 2025-03-25 | — | — | CN | disclosed |
| EP-4455159-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS WITH BIO-DISTRIBUTION MODIFIER | 3B Pharmaceuticals GmbH (DE) | 2024-10-30 | — | — | EP | disclosed |
| US-20240207292-A1 | BORONIC ACID COMPOUNDS, COMPOSITIONS AND METHODS | TRUSTEES OF TUFTS COLLEGE | 2024-06-27 | — | — | US | disclosed |
| US-20240207292-A1 | BORONIC ACID COMPOUNDS, COMPOSITIONS AND METHODS | TRUSTEES OF TUFTS COLLEGE | 2024-06-27 | — | — | US | disclosed |
| US-20230330275-A1 | FAP-TARGETED RADIOPHARMACEUTICALS AND IMAGING AGENTS, AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE | 2023-10-19 | — | — | US | disclosed |
| US-20230330275-A1 | FAP-TARGETED RADIOPHARMACEUTICALS AND IMAGING AGENTS, AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE | 2023-10-19 | — | — | US | disclosed |
| EP-4065176-B1 | COMBINATION OF PARA-AMINOHIPPURIC ACID (PAH) AND RADIOLABELED COMPLEXES FOR TREATING CANCER | ITM ISOTOPE TECH MUNICH SE (DE) | 2023-10-11 | — | — | EP | disclosed |
| WO-2023165987-A1 | PRECURSOR MARKERS AND RADIOTRACERS WITH THREE OR MORE TARGETING VECTORS FOR THERANOSTICS USED IN NUCLEAR MEDICINE | Atoms for Cure GmbH (DE) | 2023-09-07 | — | — | WO | disclosed |
| US-20230248854-A1 | METHOD FOR PRODUCING RADIOACTIVE METAL-LABELED ANTIBODY | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2023-08-10 | — | — | US | disclosed |
| US-6770020-B2 | NEUTRON CAPTURE THERAPY (NCT) USING GADOLINIUM DIETHYLENETRIAMINEPENTAACETIC ACID; TREATING GLIOBLASTOMAS, GLIOMAS | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2004-08-03 | — | — | US | disclosed |
| US-20040067924-A1 | Actinium-225 complexes and conjugates for targeted radiotherapy | FRANK R KEITH (US) | 2004-04-08 | — | — | US | disclosed |
| US-6670456-B2 | For therapy of cancer | DOW GLOBAL TECHNOLOGIES INC. | 2003-12-30 | — | — | US | disclosed |
| EP-1370301-A2 | ACTINIUM-225 COMPLEXES AND CONJUGATES FOR TARGETED RADIOTHERAPY | DOW GLOBAL TECHNOLOGIES INC. (US) | 2003-12-17 | — | — | EP | disclosed |
| US-20030086868-A1 | Actinium-225 complexes and conjugates for radioimmunotherapy | MA DANGSHE (US) | 2003-05-08 | — | — | US | disclosed |
| US-20030049202-A1 | Method of using gadolinium neutron capture to treat cancers | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2003-03-13 | — | — | US | disclosed |
| US-20030023050-A1 | Actinium-225 complexes and conjugates for targeted radiotherapy | DOW GLOBAL TECHNOLOGIES INC. | 2003-01-30 | — | — | US | disclosed |
| WO-2002067999-A3 | ACTINIUM-225 COMPLEXES AND CONJUGATES FOR TARGETED RADIOTHERAPY | DOW GLOBAL TECHNOLOGIES INC (US) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002067999-A2 | ACTINIUM-225 COMPLEXES AND CONJUGATES FOR TARGETED RADIOTHERAPY | DOW GLOBAL TECHNOLOGIES INC. (US) | 2002-09-06 | — | — | WO | disclosed |
| WO-1995001346-A1 | CHELATING COMPOUNDS | AKZO NOBEL N.V. (NL) | 1995-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230330275-A1 | FAP-TARGETED RADIOPHARMACEUTICALS AND IMAGING AGENTS, AND USES RELATED THERETO | FAP, APC, FIBP | HSD17B10 3607/4885SLC6A9 4564/4885ALDH1A1 1322/4885 |
| US-20030023050-A1 | Actinium-225 complexes and conjugates for targeted radiotherapy | CCR5, CXCR1, CCR9 | HSD17B10 2223/4885SLC6A9 2137/4885ALDH1A1 4384/4885 |
| US-20030049202-A1 | Method of using gadolinium neutron capture to treat cancers | NUCB2, MKI67, GMNN | HSD17B10 3436/4885SLC6A9 620/4885ALDH1A1 4571/4885 |
| US-20230248854-A1 | METHOD FOR PRODUCING RADIOACTIVE METAL-LABELED ANTIBODY | CD4, PTMS, TAC3 | HSD17B10 2060/4885SLC6A9 1953/4885ALDH1A1 4185/4885 |
| US-20240207292-A1 | BORONIC ACID COMPOUNDS, COMPOSITIONS AND METHODS | BCL6B, BCL6, BTD | HSD17B10 2957/4885SLC6A9 705/4885ALDH1A1 3873/4885 |
| US-20040067924-A1 | Actinium-225 complexes and conjugates for targeted radiotherapy | CCR5, CXCR5, CXCR1 | HSD17B10 2035/4885SLC6A9 2187/4885ALDH1A1 4269/4885 |
| US-20030086868-A1 | Actinium-225 complexes and conjugates for radioimmunotherapy | H1-5, CHRND, H1-2 | HSD17B10 3558/4885SLC6A9 3893/4885ALDH1A1 4111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.